Clinical outcomes of non-curative endoscopic submucosal dissection with negative resected margins for gastric cancer

Gastrointest Endosc. 2017 Jun;85(6):1218-1224. doi: 10.1016/j.gie.2016.11.018. Epub 2016 Nov 24.

Abstract

Background and aims: There has been little information about the long-term outcomes of patients with early gastric cancer (EGC) treated by non-curative endoscopic submucosal dissection (ESD) with negative resected margins (R0 resection). We aimed to compare the clinical outcomes of non-curative ESD with R0 resection between patients who underwent additional gastrectomy and those who did not.

Methods: Among EGC patients treated by ESD from 2002 to 2010, 66 patients were treated by non-curative ESD with R0 resection. Patients received either additional gastrectomy (group A, n = 45) or were followed up without gastrectomy (group B, n = 21). The clinicopathologic findings and the subsequent clinical course were compared between the 2 groups.

Results: Patients in group A were younger than those in group B (68.0 vs 71.0 years, P = .006). The follow-up period was longer in group A than in group B (7.8 vs 5.9 years, P = .011). The percentage of patients who died of any cause was not statistically lower in group A than in group B (13.3% vs 33.3%, P = .06). Although the overall survival rate was higher in group A than in group B (93.3% vs 76.2%, P = .028), disease-specific survival rates did not differ between the 2 groups (97.8% vs 100%, P = .495). A Cox proportional hazards model showed that gastrectomy was not an independent factor associated with overall survival.

Conclusions: Careful follow-up may be an alternative strategy to gastrectomy for a subgroup of patients treated by non-curative ESD with R0 resection.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carcinoma / surgery*
  • Disease-Free Survival
  • Endoscopic Mucosal Resection / methods*
  • Female
  • Gastrectomy*
  • Gastroscopy
  • Humans
  • Male
  • Margins of Excision
  • Middle Aged
  • Proportional Hazards Models
  • Retrospective Studies
  • Stomach Neoplasms / surgery*
  • Survival Rate
  • Treatment Outcome